Harrow, Inc. (NASDAQ:HROW) Stock Position Lessened by Royce & Associates LP

Royce & Associates LP decreased its holdings in Harrow, Inc. (NASDAQ:HROW) by 33.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 360,320 shares of the company’s stock after selling 179,580 shares during the quarter. Royce & Associates LP owned 1.02% of Harrow worth $16,200,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of HROW. BNP Paribas Financial Markets grew its stake in shares of Harrow by 12.7% in the first quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock worth $224,000 after purchasing an additional 1,912 shares in the last quarter. Vanguard Group Inc. boosted its stake in Harrow by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after buying an additional 21,253 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Harrow by 6.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock valued at $221,000 after buying an additional 1,033 shares in the last quarter. Bayesian Capital Management LP bought a new position in Harrow during the first quarter valued at about $185,000. Finally, Opaleye Management Inc. boosted its stake in Harrow by 2.6% during the first quarter. Opaleye Management Inc. now owns 3,920,600 shares of the company’s stock valued at $51,870,000 after buying an additional 100,600 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Analyst Upgrades and Downgrades

HROW has been the subject of several research reports. Lake Street Capital raised their target price on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Craig Hallum raised their target price on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Finally, B. Riley reaffirmed a “buy” rating and set a $50.00 target price on shares of Harrow in a report on Thursday, August 29th.

Harrow Trading Down 9.0 %

Shares of NASDAQ HROW opened at $39.01 on Friday. Harrow, Inc. has a 12 month low of $8.01 and a 12 month high of $59.23. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -41.50 and a beta of 0.76. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18. The business has a fifty day simple moving average of $47.92 and a 200-day simple moving average of $32.28.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.